Girentuximab

Girentuximab
Monoclonal antibody
Type	Whole antibody
Source	Chimeric
Target	CA-IX
Clinical data
Trade names	Rencarex
Identifiers
CAS Number	916138-87-9^N
ATC code	none
ChemSpider	none
UNII	539B57DFJF^Y
Chemical data
Formula	C₆₄₆₀H₁₀₀₀₆N₁₇₁₈O₂₀₁₈S₄₈
Molar mass	146.5 kg/mol
^NY (what is this?) (verify)

Girentuximab (trade name Rencarex) is a chimeric monoclonal antibody to carbonic anhydrase IX.^[1] It is investigational agent in clinical trials for renal cell carcinoma.^[2]

Girentuximab was developed by Wilex AG.

It triggers antibody-dependent cell-mediated cytotoxicity (ADCC). It does this by activating natural killer cells by binding to carbonic anhydrase IX.^[3]

References

↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Girentuximab" (PDF). American Medical Association.
↑ Bedke J, Stenzl A (2013). "Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?". Expert Review of Anticancer Therapy 13 (12): 1399–408. doi:10.1586/14737140.2013.856761. PMID 24215158.
↑ Girentuximab (Rencarex) for renal cell carcinoma

Monoclonal antibodies for tumors

Tumor
("-t(u[m])-")

Human ("-tumu-")	Adecatumumab Cixutumumab Conatumumab Daratumumab Drozitumab Duligotumab Dusigitumab Enfortumab vedotin Figitumumab Ganitumab Glembatumumab vedotin Intetumumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Narnatumab Necitumumab Ofatumumab Olaratumab Panitumumab Patritumab Pritumumab Radretumab Rilotumumab Robatumumab Seribantumab Teprotumumab Tovetumab Vantictumab Votumumab Zalutumumab "-melu-" (melanoma) Flanvotumab

Mouse ("-tumo-")	Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Detumomab Ibritumomab tiuxetan Minretumomab Mitumomab Moxetumomab pasudotox Naptumomab estafenatox Nofetumomab merpentan Pemtumomab^† Pintumomab Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Tenatumomab Tositumomab 3F8 "-govo-" (ovarian tumor) Abagovomab Igovomab Oregovomab "-pro-" (prostate tumor) Capromab pendetide "-colo-" (colonic tumor) Edrecolomab Nacolomab tafenatox

Chimeric ("-tuxi-")	Amatuximab Bavituximab Brentuximab vedotin Cetuximab Derlotuximab biotin Dinutuximab Ensituximab Futuximab Girentuximab Indatuximab ravtansine Isatuximab Margetuximab Rituximab Siltuximab Ublituximab "-mexi-" (melanoma): Ecromeximab

Humanized ("-tuzu-")	Alemtuzumab Bevacizumab Bivatuzumab mertansine Cantuzumab mertansine Cantuzumab ravtansine Citatuzumab bogatox Clivatuzumab tetraxetan Dacetuzumab Dalotuzumab Elotuzumab^† Emibetuzumab Enoblituzumab Etaracizumab Farletuzumab Ficlatuzumab Gemtuzumab ozogamicin Imgatuzumab Inotuzumab ozogamicin Labetuzumab Lifastuzumab vedotin Lintuzumab Lorvotuzumab mertansine Matuzumab^§ Milatuzumab Nimotuzumab Obinutuzumab Ocaratuzumab Otlertuzumab Onartuzumab Oportuzumab monatox Parsatuzumab Pertuzumab Pinatuzumab vedotin Polatuzumab vedotin Sibrotuzumab Simtuzumab Tacatuzumab tetraxetan Tigatuzumab Trastuzumab Tucotuzumab celmoleukin Veltuzumab Vorsetuzumab mafodotin "-gozu-" (ovarian tumor) Sofituzumab vedotin

Rat/mouse hybrid ("-tumaxo-")	Catumaxomab Ertumaxomab

Chimeric + humanized ("-tuxizu-")	Ontuxizumab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Sunday, March 06, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.